Sumitomo Mitsui Trust Group, Inc. 13D and 13G filings for Takeda Pharmaceutical Company Limited:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-05 06:24 am Sale | 2023-12-31 | 13G | Takeda Pharmaceutical Company Limited TAK | Sumitomo Mitsui Trust Group, Inc. | 87,400,834 5.500% | -6,198,700 (-6.62%) | Filing |
| 2023-02-03 06:19 am Purchase | 2022-12-31 | 13G | Takeda Pharmaceutical Company Limited TAK | Sumitomo Mitsui Trust Group, Inc. | 93,599,534 5.900% | 2,685,800 (+2.95%) | Filing |
| 2022-02-04 06:09 am Sale | 2021-12-31 | 13G | Takeda Pharmaceutical Company Limited TAK | Sumitomo Mitsui Trust Group, Inc. | 90,913,734 5.700% | -3,120,300 (-3.32%) | Filing |
| 2021-02-05 06:10 am Purchase | 2020-12-31 | 13G | Takeda Pharmaceutical Company Limited TAK | Sumitomo Mitsui Trust Group, Inc. | 94,034,034 6.000% | 94,034,034 (New Position) | Filing |